Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection

NCT01830127 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01830127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01830127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
October 31, 2014
Enrollment
35 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic